Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal irinotecan versus conventional irinotecan plus 5-FU/LV with optional bevacizumab or cetuximab as first-line treatment for advanced colorectal cancer
ChiCTR2400084373Phase 2Not yet recruiting
- Sponsor
- Mianyang Central Hospital
- Start
- May 2024
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of irinotecan liposome and irinotecan in colorectal cancer (CRC) (2 arms), sponsored by Mianyang Central Hospital. Primary endpoint: Progression-free survival. Planned start May 2024; status: not yet recruiting.
02
Drugs
irinotecan liposomeirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2400084373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084373.